Insider at Ligand Pharmaceuticals (LGND) Makes Significant Sale of Stock

Friday, March 09, 2018 10:15 PM ET

Insider at Ligand Pharmaceuticals (LGND) Makes Significant Sale of Stock

One Ligand Pharmaceuticals insider Jason Aryeh, Director, today, disposed of 7,500 shares having a market value of approximately $1,317,994, as revealed in a form 4 document filed with the SEC. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 25,925 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 33,425 shares and have averaged 8,356 shares per transaction over this time period.

Over the last 90 days, the number of insider buy/sell trades at Ligand Pharmaceuticals is greater than its 191-company peer group average. The Biotechnology & Medical Research peer group saw 177 buy/sell trades during this period for an average of 0.9 transactions per company. However, the number of shares traded per transaction by Ligand Pharmaceuticals insiders is lower than its peers. Within the peer group there were 11,127,908 shares purchased and 6,944,993 shares sold with company insiders purchasing 36,692 shares on average over this time period.

The data used in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.